Belinda S. Cowling is a French medical researcher and cofounder and scientific advisor of the biotech firm Dynacure, which was founded in 2016.
As Dynacure's Chief Scientific Officer,[1] her focus is on translational research and drug-candidate development.
[2] In 2019, she was awarded the Irène Joliot-Curie Prize in the category: Women, Research and Enterprise.
She moved to France to take an internship at the Institute of Genetics, Molecular and Cellular Biology (IGBMC), Strasbourg, and joined the team of Jocelyn Laporte where she studied the normal biological function of the protein, dynamin-2 (DNM2).
The research strategy that she set up allows the pathology to be tackled on several fronts, from fundamental aspects to clinical trials.